Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02176980 · ClinicalTrials.gov registry record · NA
Hepatitis C Alcohol Reduction Treatment
A NA study of Hepatitis C, Chronic; AUD, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 182
- Enrollment target
- 1
- Study location
NCT02176980: Completed NA study of Hepatitis C, Chronic; AUD, sponsored by Duke University.
NCT02176980 is a NA study of Hepatitis C, Chronic; AUD that has completed, run by Duke University. The registered enrollment target is 182 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02176980, a NA study of Hepatitis C, Chronic; AUD, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 182 participants
- Enrollment target
- 1
- Study location
Study Summary
Subjects are being asked to take part in a research study to test two levels of alcohol services for patients with hepatitis C virus (HCV) who drink alcohol. The two levels differ in intensity of alcohol services and in whether or not they include a focus on liver health. The study will look at which level of alcohol services best decreases alcohol use among patients with HCV.
Primary Outcome
Investigators will compare the two treatment arms on occurrence and amount of past 180 days of drinking using the timeline follow-back method, allowing the investigators to assess change in number of drinking days, periods of abstinence, and total grams of alcohol consumed.
Conditions Studied
Interventions
- BEHAVIORAL Brief alcohol counseling
- BEHAVIORAL Group and Individual Therapy Sessions
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2014-10 |
| Est. Completion | 2018-09-30 |
| Phase | NA |
What the finished NCT02176980 record still lists
NCT02176980 is an interventional study that assigns participants to a tested intervention. The registered 182 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Hepatitis C, Chronic; AUD appearing as the primary indexed condition, and to 2 interventions - of which Brief alcohol counseling is the first listed.
NCT02176980 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT02176980 about?
NCT02176980 is a clinical study titled "Hepatitis C Alcohol Reduction Treatment". Subjects are being asked to take part in a research study to test two levels of alcohol services for patients with hepatitis C virus (HCV) who drink alcohol. The two levels differ in intensity of alcohol services and in whether or not they include a focus on liver health. The study will look at whic...
What is the current status of trial NCT02176980?
This trial is currently completed. It is a NA study. The enrollment target is 182 participants. The study started on 2014-10. Estimated completion is 2018-09-30.
What conditions does trial NCT02176980 study?
This clinical trial studies the following conditions: Hepatitis C, Chronic; AUD.
What interventions are being tested in trial NCT02176980?
The interventions under investigation include: Brief alcohol counseling (BEHAVIORAL), Group and Individual Therapy Sessions (BEHAVIORAL).
Who is sponsoring clinical trial NCT02176980?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02176980 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02176980's enrollment target sits among peer trials
182 584th of 2000 higher than 1,415 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03897998 · 182 participants · Phase 2
Neural Correlates of Hypoalgesia Driven by Observation
- NCT04300556 · 182 participants · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
- NCT04323735 · 182 participants · Phase 2
Intravesical Lactobacillus for Urinary Symptoms Among People With NLUTD Who Use Indwelling Catheters
- NCT05606731 · 182 participants · NA
Family Intervention to Prevent Childhood Obesity
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia